Oncotarget

Research Papers:

Predictive value of glucose transporter-1 and glucose transporter-3 for survival of cancer patients: A meta-analysis

Xiu Chen, Peng Lu, Siying Zhou, Lei Zhang, Jian-hua Zhao and Jin-hai Tang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:13206-13213. https://doi.org/10.18632/oncotarget.14570

Metrics: PDF 2238 views  |   HTML 2390 views  |   ?  


Abstract

Xiu Chen2,*, Peng Lu3,*, Siying Zhou1,*, Lei Zhang4, Jian-hua Zhao5, Jin-hai Tang1,2

1The First Clinical School of Nanjing University of Chinese Medicine, Nanjing, China

2Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, First Affiliated Hospital of Nanjing Medical University, Nanjing, China

3School of Public Health Nanjing Medical University, Nanjing, China

4Xuzhou Medical University, Xuzhou, China

5Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing, China

*These authors have contributed equally to this work

Correspondence to:

Jin-hai Tang, email: [email protected]

Keywords: glucose transporter, GLUT, survival, cancer, meta-analysis

Received: July 14, 2016     Accepted: December 27, 2016     Published: January 10, 2017

ABSTRACT

Background and Objective: The role of glucose transporters in cancers remains contradictory. We conducted a systematic review and meta-analysis to assess the association between overall survival and glucose transporter s (GLUTs) 1 and 3 to find an accurate prognostic biomarker.

Methods: We systematically searched the PubMed, EMbase and Medline databases for relevant published studies that were consistent with the eligible criteria up to January 2016, and calculated pooled estimated hazard ratios of GLUT-1 and -3's expressions in different cancer types and ethnic populations. Random-effects models were used to assess estimates from studies with significant heterogeneities.

Results: Overall, 12 studies concerning GLUT 1 and 2 studies concerning GLUT 3, which involved 2008 participants when combined, were included in this analysis. We found that overexpression of GLUTs were significantly correlated to poorer survival rates (HR=1.63, 95%CI=1.09-2.44 and HR=1.89, 95%CI=1.28-2.81). In the subgroup analysis, the GLUT 1 up-regulation was correlated with negative overall survival in pancreatic cancer and gastric cancer and with better overall survival in colorectal cancer. In addition, overexpression of GLUT 1 was associated with a poorer prognosis in the Asian population, while no significance was found in the non-Asian subgroup. However, limitations do exist, which could be handled better.

Conclusions: A combination of GLUTs 1 and 3 might help predict malignancy of cancers and direct effective cancer therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14570